HOME >> MEDICINE >> NEWS
$7.5 million NIH grant to Yale for Autism Center of Excellence

The Yale Child Study Center has been awarded the Autism Center of Excellence (ACE) status by the National Institutes of Health. This highly competitive and prestigious award comes with $7.5 million of direct funding over five years to the Autism Program led by Ami Klin.

This is our largest award to date, and signifies a recognition of the national leadership in research of autism provided by our interdisciplinary group of clinical scientists, said Klin, the Harris Associate Professor of Child Psychology & Psychiatry in the Child Study Center. The Yale ACE will further strengthen our commitment to finding the causes of autism and developing more effective treatments.

Klins colleagues on the Yale ACE include Fred Volkmar, Robert Schultz, Warren Jones, Kasia Chawarska, Rhea Paul, Matthew State, Elena Grigorenko and Joseph Chang. The team plans three longitudinal projects focused on infants with autism aged 12 to 24 months. Another project involves neuroimaging studies of a cohort of children evaluated at various stages in their development, first at two years of age, then at four and eight and finally at 10-years-old. The researchers hope to trace underlying mechanisms of brain growth and specialization of individuals with autism. A fifth project focuses on a family of genes and linked proteins found to be associated with forms of autism.

Autism is a complex brain disorder that inhibits a persons ability to communicate and develop social relationships, and it is often accompanied by extreme behavioral challenges. Autism affects about two million Americans. Autism Spectrum Disorders are diagnosed in one in 150 children in the United States and affects four times as many boys as girls. Researchers do not know how many subtypes of autism exist. There are probably several causes giving rise to this neurodevelopmental syndrome, but researchers have found that it is the most strongly genetic condition among all developmental disorders. '"/>

Contact: Karen Peart
karen.peart@yale.edu
203-432-1326
Yale University
26-Apr-2007


Page: 1 2

Related medicine news :

1. Damon Runyon renews its $2.25 million investment to support young clinical cancer investigators
2. Split the difference: Pill-splitting study looks at cost-saving step that could be used by millions
3. FPG receives $8 million for autism research
4. CIRM awards $3.79 million to Burnham Institute
5. The Burroughs Wellcome Fund awards $8 million to infectious disease investigators
6. Scripps Research awarded $17 million for adult stem cell use to treat eye diseases
7. Mayor of New York proposes preventing 100 million deaths from tobacco
8. Menzies School of Health Research receives $5.3 million in Federal Budget
9. $30 million boost to dementia research
10. $1.5 million awarded for palliative care research
11. UD receives $1.9 million for new spintronics center

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: million NIH grant Yale for Autism Center Excellence

(Date:5/21/2013)... DISCcert has served the training industry ... 17 DISC applications at the July 25 & 26th ... The July 25 & 26th DISC certification in San ... applying DISC. The time-tested, proven support materials will include ... DISC training materials ; worksheets, handouts, learning activities, ...
(Date:5/21/2013)... York, New York (PRWEB) May 21, 2013 ... to protecting the rights of victims injured by defective ... Journal of Bone & Joint Surgery on May 15, ... can be used to identify complications that occur in ... any symptoms of failure. ( http://www.jbjs.org/article.aspx?articleid=1684770 ) ...
(Date:5/21/2013)... May 2013, Paris, France: The Orsiro stent, which ... a biodegradable polymer, demonstrated non-inferiority to the Xience ... of in-stent late lumen loss at nine months ... at EuroPCR 2013 today. , The BIOFLOW-II substudy ... (OCT) to quantitatively assess neointimal hyperplasia and stent ...
(Date:5/21/2013)... OR (PRWEB) May 21, 2013 Phoseon ... systems at the 20th Annual IMI European Ink ... a proven market leader, Phoseon continues to invest in ... accelerating the adoption of UV LED curing in printing ... product families on the market offering both air cooled ...
(Date:5/21/2013)... 2013) A paper recently published in the ... physicians and scientists at the University of Colorado School ... for pulmonary fibrosis can be used to identify individuals ... looked at a fairly common variant of the gene ... the mucous produced by the bronchial tubes. While this ...
Breaking Medicine News(10 mins):Health News:DISCcert Offers 17 Applications in Coming DISC Certification 2Health News:DISCcert Offers 17 Applications in Coming DISC Certification 3Health News:DISCcert Offers 17 Applications in Coming DISC Certification 4Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2
(Date:5/21/2013)... Md. , May 21, 2013 ... disposable drug-free consumer electronic devices, announced that CEO, ... presenting today to the FDA,s Medical Advisory Committee, ... the company,s products for over the counter sales. ... FDA developed its medical device classification schema," Whelan ...
(Date:5/21/2013)... 21, 2013 Reportlinker.com announces that ... in its catalogue:   ... Optical Coherence Tomography (OCT) ... OBJECTIVES   BCC,s ... offer synopsis of the current and future ...
(Date:5/21/2013)... TARRYTOWN, N.Y. , May 21, 2013 /PRNewswire/ ... Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the ... positive Phase 2a study results of dupilumab (SAR231893/REGN668) in ... monoclonal antibody targeting the alpha subunit of the interleukin ... IL-4 and IL-13, drivers of Th2 (Type 2 helper ...
Breaking Medicine Technology:BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 4Global Markets and Technologies for Optical Coherence Tomography (OCT) 5Global Markets and Technologies for Optical Coherence Tomography (OCT) 6Global Markets and Technologies for Optical Coherence Tomography (OCT) 7Global Markets and Technologies for Optical Coherence Tomography (OCT) 8Global Markets and Technologies for Optical Coherence Tomography (OCT) 9Global Markets and Technologies for Optical Coherence Tomography (OCT) 10Global Markets and Technologies for Optical Coherence Tomography (OCT) 11Global Markets and Technologies for Optical Coherence Tomography (OCT) 12Global Markets and Technologies for Optical Coherence Tomography (OCT) 13Global Markets and Technologies for Optical Coherence Tomography (OCT) 14Global Markets and Technologies for Optical Coherence Tomography (OCT) 15Global Markets and Technologies for Optical Coherence Tomography (OCT) 16Global Markets and Technologies for Optical Coherence Tomography (OCT) 17Global Markets and Technologies for Optical Coherence Tomography (OCT) 18Global Markets and Technologies for Optical Coherence Tomography (OCT) 19Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7
Cached News: